Industries Ltd ADR (NYSE: TEVA) surged 6.2% while Alvotech SA (NASDAQ: ALVO) climbed 3.5% in premarket trading today, ...

Selarsdi, a biosimilar to Stelara, is approved for adult and pediatric psoriatic arthritis, plaque psoriasis, Crohn disease, ...

In 2021, Sly, biochemistry professor Harry Brumer, and a group of other researchers at the UBC developed GlycoCage, a ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has reported that the FDA has approved the biosimilar treatment ...

Sabina Ali, MD (front) uses a new intestinal ultrasound (IUS) machine on Dhiya Ravikumar (back) at the UCSF Benioff ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable clinical and endoscopic remission through 92 weeks in adults with moderately to ...

New guidelines have been developed for the monitoring of patients with inflammatory bowel disease in an effort to prevent them going on to ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the Company has secured multiple market access ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...